Hemcheck Sweden AB has received an evaluation order from the International Agency for Research on Cancer (IARC) regarding reader and disposable tests (s-Test). The order is of minor economical value and the purpose is to evaluate if Hemcheck’s products can be part of routine work for quality control of samples at IARC.
–It is very positive that IARC want to evaluate the possibility to use our products, since it’s a very interesting potential global partner. This is hopefully a first step in a longer and broader collaboration with IARC, says Joen Averstad, CEO of Hemcheck.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
The International Agency for Research on Cancer is the World Health Organisation (WHO) and United Nations (UN) organisation that performs and coordinates both laboratory- and epidemiological research to internationally fight cancer. IARC was founded in 1965 and is headquartered in Lyon, France.
Read more at https://www.iarc.who.int
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.